CA2013544A1 - Anticorps contre les produits de gene de retinoblastome et ses utilisations - Google Patents

Anticorps contre les produits de gene de retinoblastome et ses utilisations

Info

Publication number
CA2013544A1
CA2013544A1 CA2013544A CA2013544A CA2013544A1 CA 2013544 A1 CA2013544 A1 CA 2013544A1 CA 2013544 A CA2013544 A CA 2013544A CA 2013544 A CA2013544 A CA 2013544A CA 2013544 A1 CA2013544 A1 CA 2013544A1
Authority
CA
Canada
Prior art keywords
gene product
retinoblastoma gene
uses therefor
product antibodies
retinoblastoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2013544A
Other languages
English (en)
Other versions
CA2013544C (fr
Inventor
Yuen Kai Fung
Anne T'ang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canji Inc
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of CA2013544A1 publication Critical patent/CA2013544A1/fr
Application granted granted Critical
Publication of CA2013544C publication Critical patent/CA2013544C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4736—Retinoblastoma protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cosmetics (AREA)
CA002013544A 1989-03-31 1990-03-30 Anticorps contre les produits de gene de retinoblastome et ses utilisations Expired - Fee Related CA2013544C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33208289A 1989-03-31 1989-03-31
US332,082 1989-03-31

Publications (2)

Publication Number Publication Date
CA2013544A1 true CA2013544A1 (fr) 1990-09-30
CA2013544C CA2013544C (fr) 2001-02-06

Family

ID=23296661

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002013544A Expired - Fee Related CA2013544C (fr) 1989-03-31 1990-03-30 Anticorps contre les produits de gene de retinoblastome et ses utilisations

Country Status (15)

Country Link
EP (1) EP0390530B1 (fr)
JP (1) JPH04193900A (fr)
KR (1) KR0175658B1 (fr)
CN (1) CN1046759A (fr)
AT (1) ATE122723T1 (fr)
AU (1) AU638238B2 (fr)
CA (1) CA2013544C (fr)
DE (1) DE69019410T2 (fr)
FI (1) FI901618A7 (fr)
IE (1) IE63277B1 (fr)
IL (1) IL93941A (fr)
NO (1) NO179328C (fr)
NZ (1) NZ233147A (fr)
PT (1) PT93619A (fr)
ZA (1) ZA902425B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102053150A (zh) * 2009-10-30 2011-05-11 上海交通大学医学院附属瑞金医院 一种人成骨肉瘤干细胞相关抗原标记物及其应用

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001467A1 (fr) * 1992-07-14 1994-01-20 Canji, Inc. Caracterisation d'un nouvel anticorps monoclonal anti-p110?rb¿
US5550020A (en) * 1994-07-08 1996-08-27 Visible Genetics Inc. Method, reagents and kit for diagnosis and targeted screening for retinoblastoma
US5545527A (en) * 1994-07-08 1996-08-13 Visible Genetics Inc. Method for testing for mutations in DNA from a patient sample
JP2000510330A (ja) * 1996-04-05 2000-08-15 トーマス・ジェファーソン・ユニバーシティ 癌の診断および予後のための方法
US5840506A (en) * 1996-06-05 1998-11-24 Thomas Jefferson University Methods for the diagnosis and prognosis of cancer
EP2181704B1 (fr) 2002-12-30 2015-05-06 Angiotech International Ag Liberation de médicaments a partir d'une composition polymère à gélification rapide
TW200741009A (en) 2005-07-01 2007-11-01 Oncotherapy Science Inc Methods of modulating SMYD3 for treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006703A1 (fr) * 1988-01-21 1989-07-27 Massachusetts Eye And Ear Infirmary Diagnostic du retinoblastome

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102053150A (zh) * 2009-10-30 2011-05-11 上海交通大学医学院附属瑞金医院 一种人成骨肉瘤干细胞相关抗原标记物及其应用
CN102053150B (zh) * 2009-10-30 2013-07-17 上海交通大学医学院附属瑞金医院 一种人成骨肉瘤干细胞相关抗原标记物及其应用

Also Published As

Publication number Publication date
DE69019410T2 (de) 1995-10-05
NZ233147A (en) 1993-04-28
IL93941A (en) 1995-03-30
EP0390530A1 (fr) 1990-10-03
CA2013544C (fr) 2001-02-06
NO179328C (no) 1996-09-18
PT93619A (pt) 1990-11-20
AU5246190A (en) 1990-10-04
IE63277B1 (en) 1995-04-05
ATE122723T1 (de) 1995-06-15
DE69019410D1 (de) 1995-06-22
KR900013987A (ko) 1990-10-22
NO179328B (no) 1996-06-10
FI901618A7 (fi) 1990-10-01
ZA902425B (en) 1991-01-30
IL93941A0 (en) 1990-12-23
NO901461D0 (no) 1990-03-30
KR0175658B1 (ko) 1999-03-20
NO901461L (no) 1990-10-01
IE901179L (en) 1990-09-30
CN1046759A (zh) 1990-11-07
EP0390530B1 (fr) 1995-05-17
JPH04193900A (ja) 1992-07-13
FI901618A0 (fi) 1990-03-30
AU638238B2 (en) 1993-06-24

Similar Documents

Publication Publication Date Title
SG96535A1 (en) Pharmaceutical composition for the treatment or prevention of a malignant tumor
EP0288082A3 (fr) Essai tumeur-spécifique pour le CA125 antigène du cancer ovarien
AUPN568095A0 (en) Anti-Galalpha(1,3)Gal antibody binding peptides
TW428026B (en) Bifunctional protein, preparation and use
EP1808155A3 (fr) Hybrides de protéines de sérum d'anticorps
WO1999033869A3 (fr) Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation
IL96907A0 (en) Proteins produced by human lymphocytes,a dna sequence coding for said proteins and their pharmaceutical and biological application
CA2034504A1 (fr) Proteines de champignon produites a la suite d'un stress
CA2082382A1 (fr) Proteines de surface cd44 variantes, sequences d'adn codant pour ces proteines, anticorps contre ces proteines et utilisation de ces proteines a des fins diagnostiques et therapeutiques
AU3125289A (en) Monoclonal antibodies directed against human tumor necrosis factor - receptor
CA2295999A1 (fr) Proteines nik, acides nucleiques et procedes correspondants
WO1993018146A3 (fr) Proteines formant des complexes avec des chaperones et leurs ligands, leurs fragments, leur obtention et leurs applications biologiques
AU3069584A (en) Peptides, pharmaceutical compositions,genes,vectors,host organisms, processes for there production and diagnostic reagents
WO1997029199A3 (fr) Peptides pour l'antigene prostatique specifique et leurs utilisations
CA2013544A1 (fr) Anticorps contre les produits de gene de retinoblastome et ses utilisations
CA2008304A1 (fr) Dosage de la phosphatase alcaline des os
EP0921194A3 (fr) TRAILLK-2: membre de la famille des ligand du TNF
CA2340888A1 (fr) Nouvelle proteine d'antigene tumoral sart-3 et peptide d'antigene tumoral de celle-ci
EP0919620A3 (fr) TRAILLK-3: Membre de la famille des ligands du TNF
CA2067797A1 (fr) Production et utilisation de la proteine humaine nm23 et anticorps necessaires a cette fin
AU649961B2 (en) Method for protein binding enzyme complementation assays
AU6873587A (en) Monoclonal antibodies useful in the identification of microorganisms causing peridontal disease
WO1994028129A3 (fr) Gene de metastase de tumeur
EP1961820A3 (fr) Acides nucléiques associés à la tumeur LAG-1
CA2199403A1 (fr) Nouvelles proteines fixant la proteine kinase a (pka) et leur utilisation

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed